Breaking News

Financial Report: Alkermes

By Kristin Brooks | February 27, 2014

Revenues up 14% in the quarter


3Q Revenues: $154.5 million (+14%)

3Q Earnings: $18.1 million (+11%)

YTD Revenues: $432.9 million (+5%)

YTD Earnings: $17.6 million (-20%)

Comments: Manufacturing and royalty revenues in the quarter were $132.7 million, up 12%, driven by the atypical antipsychotic franchise, up 36% to $71.2 million. Product sales were $20.6 million, up 29% driven by and VIVITROL, with sales up 30% to $20.6 million. R&D revenues were $1.2 million, down 31%.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks